Patent case: Samsung Bioepis UK Ltd. vs. Janssen Biotech Inc., Netherlands

The basic patent and SPC on Stelara®, the successful blockbuster drug of Janssen, have expired, which means that the generic producer Samsung Bioepis can potentially bring its generic drug on the market. However, Janssen still holds a patent on a second medical use of the drug for the treatment of ulcerative colitis. Samsung tried to argue (as it had successfully done in the UK) that this patent was invalid. The Dutch first instance court, however, held Janssen’s patent to be valid.

Case date: 10 September 2025
Case number: HA ZA 24-44
Court: District Court of The Hague, C/09/659616

A full summary of this case has been published on Kluwer IP Law